Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)

BACKGROUND: Takeda’s live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have reported its efficacy and safety in both seronegative and seropositive participants and that its performance va...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivera, Luis, Biswal, Shibadas, Sáez-Llorens, Xavier, Reynales, Humberto, López-Medina, Eduardo, Borja-Tabora, Charissa, Bravo, Lulu, Sirivichayakul, Chukiat, Kosalaraksa, Pope, Martinez Vargas, Luis, Yu, Delia, Watanaveeradej, Veerachai, Espinoza, Felix, Dietze, Reynaldo, Fernando, LakKumar, Wickramasinghe, Pujitha, Duarte MoreiraJr, Edson, Fernando, Asvini D, Gunasekera, Dulanie, Luz, Kleber, Venâncioda Cunha, Rivaldo, Rauscher, Martina, Zent, Olaf, Liu, Mengya, Hoffman, Elaine, LeFevre, Inge, Tricou, Vianney, Wallace, Derek, Alera, MariaTheresa, Borkowski, Astrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402653/
https://www.ncbi.nlm.nih.gov/pubmed/34606595
http://dx.doi.org/10.1093/cid/ciab864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402653/
https://www.ncbi.nlm.nih.gov/pubmed/34606595
http://dx.doi.org/10.1093/cid/ciab864

Ejemplares similares